All In Biotech

Drug Trial Radar · NCT04992260

Efficacy, Immunogenicity and Safety of COVID-19 Vaccine , Inactivated in Children and Adolescents

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase Ⅲ Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of COVID-19 Vaccine(Vero Cell) ,Inactivated in Children and Adolescents Aged 6 Months to 17 Years

Last checked: Nov 20, 2026Latest source record: Oct 16, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 11,349 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

11,349

Actual

Start

Sep 10, 2021

Primary completion

May 31, 2023

Study completion May 31, 2023

Sponsor

Sponsor type
Industry
First posted
Aug 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 6 months, up to 17 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a global multi-center , case-driven, randomized, double-blinded, and placebo-controlled phase Ⅲ clinical trial of the SARS-CoV-2 inactivated vaccine manufactured by Sinovac Research \& Development Co., Ltd. The purpose of this study is to evaluate the efficacy of two dose of CoronaVac® against RT-PCR confirmed symptomatic COVID-19 cases in participants aged 6 months to 17 years.

Conditions

  • COVID-19

Interventions

  • Inactivated COVID-19 VaccineBiological

    The inactivated COVID-19 vaccine was manufactured by Sinovac Research\& Development Co., Ltd..600SU Inactivated SARS-COV-2 virus in 0·5 mL of aluminium hydroxide solution per injection

  • Controlled vaccineBiological

    The placebo was manufactured by Sinovac Research\& Development Co., Ltd.The composition is aluminium hydroxide,The appearance of the placebo is consistent with the vaccine, which is a milky-white suspension.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy index-incidence of RT-PCR confirmed symptomatic COVID-19 cases with onsetTime frame: 14 days after the second dose

Locations

38 sites in 4 countries. Site status is shown where the registry gives one.

  • Hospital de Puerto Montt

    Port Montt, Los Lagos Region, Chile

  • Clínica Alemana Valdivia

    Valdivia, Los Ríos Region, Chile

  • Hospital Universidad Clinico de Antofagasta

    Antofagasta, Santiago Metropolitan, Chile

  • Hospital Roberto del Río

    Independencia, Santiago Metropolitan, Chile

  • Clínica San Carlos de Apoquindo

    Las Condes, Santiago Metropolitan, Chile

  • Clínica Universidad de los Andes

    Las Condes, Santiago Metropolitan, Chile

  • San Joaquín

    Macul, Santiago Metropolitan, Chile

  • Hospital Sótero del Río

    Puente Alto, Santiago Metropolitan, Chile

  • Hospital Ezequial Gonzalez

    San Miguel, Santiago Metropolitan, Chile

  • Marcoleta

    Santiago, Santiago Metropolitan, Chile

  • Clínica Alemana

    Vitacura, Santiago Metropolitan, Chile

  • Hospital Gustavo Fricke

    Viña del Mar, Valparaiso, Chile

  • University Malaya Medical Centre

    Kuala Lumpur, Malaysia

  • Hospital Wanita dan Kanak-Kanak Sabah

    Kota, Kinabalu Sabah, Malaysia

  • Klinik Kesihatan Cheras Baru

    Cheras, Kuala Lumpur, Malaysia

  • Hospital Raja Permaisuri Bainun

    Ipoh, Perak, Malaysia

  • Hospital Seberang Jaya

    Seberang Jaya, Pulau Pinang, Malaysia

  • Hospital Miri

    Miri, Sarawak, Malaysia

  • Hospital Sibu

    Sibu, Sarawak, Malaysia

  • Hospital Pengajar UiTM Puncak Alam

    Bandar, Selangor, Malaysia

  • Klinik Kesihatan Pandamaran

    Port Klang, Selangor, Malaysia

  • Hospital Sungai Buloh

    Sungai Buloh, Selangor, Malaysia

  • Asian Hospital and Medical Center

    City of Muntinlupa, Philippines

  • National Children's Hospital

    Manila, Philippines

  • Philippine Children's Medical Center

    Manila, Philippines

  • Philippine General Hospital

    Manila, Philippines

  • University of Philippines, National Institute of Health

    Manila, Philippines

  • Mecru Clinical Research Unit

    Bellville, South Africa

  • Tiervlei Trial Centre

    Bellville, South Africa

  • Worthwhile Clinical Trials

    Benoni, South Africa

  • Reimed Reicherpark

    Boksburg, South Africa

  • Newtown Clinical Research Centre

    Johannesburg, South Africa

  • Madibeng Centre for Research

    Madibeng, South Africa

  • Be Part Research

    Paarl, South Africa

  • Global Clinical Trials

    Pretoria, South Africa

  • Sandton Medical Research Centre

    Sandton, South Africa

  • Soweto Clinical Trials Center

    Soweto, South Africa

  • Mecru Clinical Research Unit

    Ga-Rankuwa, Gauteng, South Africa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.